Copper peptide,
visible.
GHK-Cu is the naturally occurring tripeptide your body produces less and less of as you age — about 60% less by midlife than at 20. Studied for collagen remodeling, hair follicle reactivation, and the slow visible work of skin barrier repair. Available as injection or compounded topical.
From$40 / month · 8–12 week cyclesWhat GHK-Cu is.
GHK-Cu is a three-amino-acid copper-binding peptide — Glycyl-L-histidyl-L-lysine — that occurs naturally in human plasma, saliva, and urine. The "Cu" refers to the copper ion (Cu²⁺) that binds tightly to the histidine residue, which is what gives the molecule its characteristic deep blue color and its biological activity.
It was discovered in 1973 by Loren Pickart, who observed that older blood plasma stopped supporting hepatocyte regeneration in culture — and that adding GHK-Cu fully restored the effect. Plasma levels of GHK-Cu decline by roughly 60–70% between age 20 and age 60, making it one of the better-characterized "decline molecules" in human biology.
What the human evidence shows.
GHK-Cu has more dermatology-grade human evidence than most peptides in our catalog. Multiple controlled topical trials show measurable improvement in:
- Skin elasticity and dermal density on ultrasound imaging at 12 weeks.
- Wrinkle depth by both objective profilometry and blinded photo grading.
- Hyperpigmentation reduction, particularly photo-aging-related discoloration.
- Wound healing speed in surgical and burn settings.
Hair-density evidence is somewhat thinner but real — particularly when GHK-Cu is paired with established therapies like minoxidil. Subcutaneous dosing for systemic effects has fewer human trials than the topical work, though pharmacokinetic and safety data both look reasonable.
Injectable or topical?
The question your prescriber will help you answer.
Topical GHK-Cu is the right starting point for most patients focused specifically on facial skin, scalp, or a defined treatment area. Pepra's compounded topical is a 0.05% sterile preparation. You apply it morning and night to clean skin.
Subcutaneous injection is reserved for patients who want a more systemic effect — often paired with another protocol (BPC-157 for tissue recovery, or alongside a CJC/Ipamorelin run). Most patients dose 3 times per week.
Some patients run both: topical daily for the face, injectable 2–3x/week for the systemic and hair effects. Your prescriber decides if that's reasonable.
What patients actually report.
- Week 2–3. Skin "looks rested." Patients describe makeup applying differently before they consciously notice the skin change.
- Week 6–8. Texture is the most commonly reported visible change — pore appearance, fine lines around the eyes, neck skin.
- Week 12. Hair density changes (scalp users) become noticeable. Faint hyperpigmentation patches lighten.
Side-effect profile.
- Topical: mild blue-tint staining on light fabric (the copper). Occasional skin tingling at first applications. No reported sensitization in controlled studies.
- Injectable: mild local site reaction, occasional brief flushing.
- Copper accumulation is a theoretical concern with very long protocols — we monitor in patients running >6 months continuously.
Not for use during pregnancy. Patients with Wilson's disease (impaired copper metabolism) or any disorder of copper handling should not use GHK-Cu without specialist coordination.
How a typical Pepra protocol runs.
Most patients run topical daily for 12 weeks, then re-evaluate. Patients on injectable run 1–2 mg subcutaneously, 3 times per week, for 12 weeks. Both protocols can run continuously after the initial cycle, with a break every 6 months.
GHK-Cu is one of the slower-acting peptides in the Pepra catalog by design. The work it does — collagen, follicle, dermal — is structural, and structural change is patient. We tell patients to commit to a 12-week run before judging results.
Selected references
- 1.Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide" — Int J Mol Sci. 2018;19(7):1987.
- 2.Abdulghani AA, et al. "Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on photoaged skin" — Dis Manag Clin Outcomes. 1998;1(4):136-141.
- 3.Leyden J, et al. "Skin care benefits of copper peptide containing facial cream" — American Academy of Dermatology Annual Meeting. 2002.
- 4.Pyo HK, et al. "The effect of tripeptide-copper complex on human hair growth in vitro" — Arch Pharm Res. 2007;30:834-839.
- 5.Schagen SK. "Topical Peptide Treatments with Effective Anti-Aging Results" — Cosmetics. 2017;4(2):16.
- 6.Pickart L, et al. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration" — Biomed Res Int. 2015;2015:648108.